Negative ROI Companies: Agenus Inc (AGEN), Halozyme Therapeutics, Inc. (HALO), And BioDelivery Sciences International, Inc. (BDSI)

Posted by Ryan Mandell January 28, 2015 0 Comment 735 views

New York, NY – GDP INSIDER  – 01/28/2015.

Agenus Inc (NASDAQ:AGEN)’s ROI now stands at -581.40%. The stock edged up slightly by 0.19%, gaining $0.01 to end the session at $5.26. The stock exchanged hands between $5.13 low and $5.39 high in the session. AGEN opened the session at $5.20, exchanged 1.15 million shares, a volume that was below the daily average of 3.35 million shares. AGEN saw its market cap rising to $329.72 million following the slight gain, which also left the stock 131.72% above its 52-week low and 18.95% below its 52-week high. The average target price on the stock is $8.75.

Agenus Inc (NASDAQ:AGEN) grew its sales 128.60% sequentially in the most recent quarter. EPS was also up 45.80% QoQ. Insider own 6.67% of AGEN.

Could Agenus Inc Reverse From Here Or Will Momentum Continue? Get A Hint As To What’s Coming Next With A Free Trend Analysis Report

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s ROI fell to -269.80%. The biotech company saw its shares edging up 0.28% to $14.48 in yesterday’s session, having opened at $14.12. Around 1.2 million shares changed hands yesterday, against the daily average of 2.55 million. The stock traded at a session low of $14 and a high of $14.80. At the end of the session, HALO was 110.47% above its 52-week low and 14.01 below its 52-week high. Insiders own 0.70% of Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Will Halozyme Therapeutics, Inc. Continue To Trend Higher Or Are Things About To Crash? See What’s Coming Up Next For HALO With A Complimentary Trend Analysis Report

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s ROI stood at -308.20% at the end of yesterday’s session. The specialty pharmaceutical company saw its shares gain 3.66% to $13.89. The move seemed to have been triggered by a deal that the company signed for the marketing of a cancer pain drug in North America.

Close to 851,700 shares exchange hands with a trading range of a low of $13.21 and a high of $14.23. The average daily volume of the stock is 963,181 shares. BDSI’s new stock price is now 107% above its 52-week low and 24.84% below its 52-week high.

The company acquired the North American rights to an oral drug for cancer pain known as Onsolis. It acquired the marketing rights to the drug from Swedish company known as Meda AB.

Is BioDelivery Sciences International, Inc. Going To Continue To Move Higher Or Are Things About To Turn Around? See What’s In Store For BDSI With A Free Trend Report.

About HotStockGains provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.

Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit for complete risks and disclosures.

About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment